Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cocrystal Pharma Inc. COCP

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:COCP)

Fundamentals Snapshot (NDAQ:COCP)

Current News (NDAQ:COCP)

Cocrystal Pharma Announces Participation in Virtual Investor Events

GlobeNewswire 9 days ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Newsfile 12 days ago

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

GlobeNewswire December 19, 2022

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

GlobeNewswire December 1, 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

GlobeNewswire November 17, 2022

Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

GlobeNewswire November 14, 2022

Cocrystal Pharma to Participate in Two Investor Conferences in November

GlobeNewswire November 2, 2022

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

GlobeNewswire November 1, 2022

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

GlobeNewswire October 26, 2022

Opinion & Analysis (NDAQ:COCP)

No current opinion is available.

Bullboard Posts (NDAQ:COCP)

COCP ....... Early a.m runner on NR

Now in PB mode.......$1.34 Look for support sub $1.30.....stops save portfolios Cheers !
Iseneschal - July 29, 2021

COCP up in pre-market....on watch

Seems like ever since Feb 2020.....it pops on volume evry few months. Here we go again. ps: I don't chase  Cheers !
Iseneschal - May 4, 2021

RE:RE:Q3 EPS: Pipeline Remains on Track

http://www.cocrystalpharma.com/news/press-releases/detail/115/cocrystal-pharma-reports-2020-financial-results-provides
Popeye82 - April 27, 2021

RE:Q3 EPS: Pipeline Remains on Track

http://www.cocrystalpharma.com/news/press-releases/detail/114/cocrystal-pharma-extends-drug-discovery-collaboration-with
Popeye82 - April 27, 2021

Q3 EPS: Pipeline Remains on Track

Q3 EPS: Pipeline Remains on Track https://www.channelchek.com/news-channel/Cocrystal_Pharma_Inc.__COCP____Q3_EPS_Pipeline_Remains_on...
schoolofrock - November 17, 2020

Cocrystal Pharma Provides Update on Influenza A Program

BOTHELL, WA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), announces promising...
schoolofrock - October 19, 2020